Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China

BACKGROUND: The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) is the first randomized controlled trial to provide promising evidence on the efficacy of adding empagliflozin to the standard therapy in patients with Heart Failur...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yaohui, Xie, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479072/
https://www.ncbi.nlm.nih.gov/pubmed/36119747
http://dx.doi.org/10.3389/fcvm.2022.946399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479072/
https://www.ncbi.nlm.nih.gov/pubmed/36119747
http://dx.doi.org/10.3389/fcvm.2022.946399

Ejemplares similares